Innate Pharma (IPHA) Short term Debt (2017 - 2025)
Historic Short term Debt for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to $10.1 million.
- Innate Pharma's Short term Debt rose 517.29% to $10.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was $10.1 million, marking a year-over-year increase of 517.29%. This contributed to the annual value of $9.3 million for FY2024, which is 320.56% down from last year.
- Latest data reveals that Innate Pharma reported Short term Debt of $10.1 million as of Q2 2025, which was up 517.29% from $9.3 million recorded in Q4 2024.
- In the past 5 years, Innate Pharma's Short term Debt registered a high of $35.2 million during Q4 2021, and its lowest value of $2.1 million during Q4 2022.
- In the last 5 years, Innate Pharma's Short term Debt had a median value of $9.6 million in 2023 and averaged $13.0 million.
- Within the past 5 years, the most significant YoY rise in Innate Pharma's Short term Debt was 127730.66% (2021), while the steepest drop was 9988.06% (2021).
- Quarter analysis of 5 years shows Innate Pharma's Short term Debt stood at $35.2 million in 2021, then plummeted by 93.9% to $2.1 million in 2022, then skyrocketed by 348.33% to $9.6 million in 2023, then dropped by 3.21% to $9.3 million in 2024, then increased by 8.67% to $10.1 million in 2025.
- Its last three reported values are $10.1 million in Q2 2025, $9.3 million for Q4 2024, and $9.6 million during Q2 2024.